EOLS
Evolus, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$7.10
−6.21%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$7.59
From 52W high−23.66%
Volume761676.00
Market cap$468.96M
P/E (TTM)—
P/S (TTM)1.5x
Div yield—
Key dataOct 16, 2026
Open
$7.59
From 52W high
−23.66%
Volume
761676.00
Market cap
$468.96M
ValuationView details →
P/E (Fwd)
28.6x
EV/EBITDA
−81.6x
P/E (TTM)
—
RSI (14)
40.3
MomentumView details →
1D Return
−6.21%
YTD Return
+8.57%
SummaryUpdated Jun 1, 2026
Evolus, Inc. (NASDAQ:EOLS) is a performance beauty company founded in 2012 and headquartered in Newport Beach, California. The company went public in February 2018 and has established itself as a significant player in the medical aesthetics industry. Evolus focuses on developing and commercializing innovative injectable products for physicians and their patients, primarily in the United States market. The company has evolved from a single-product neurotoxin manufacturer to a comprehensive aesthetics platform offering both neurotoxin and dermal filler solutions.
Similar companies
Latest newsMore news →
Evolus entered into an option agreement with a privately held company developing an injectable hair-restoration treatment.2d agoThe U.S. Food and Drug Administration's Office of Prescription Drug Promotion issued a warning letter to Evolus Inc. in September over misleading Instagram promotional posts for its injectable drug Jeuveau.14d agoThe U.S. FDA sent a letter to Evolus, after which Evolus shares fell as much as 10%.14d ago